| abstract |
The present invention relates to an azole saskeleton compound having an antagonistic action against arginine-vasopressin (AVP) receptor V1b, as well as pharmaceutical preparations containing said compound as an active ingredient, in particular for the treatment or prevention of diseases such as mood disorders (including depression) , anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral hemorrhage, inflammation, immune system, disease. |